First Light Asset Management, LLC
13F Reported Value
ⓘ$1.6B
Holdings
31
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
First Light Asset Management, LLC disclosed 31 positions worth $1.6B in its Form 13F-HR for Q2 2026, led by $NEO (NEOGENOMICS INC) at 10.9% of the equity portfolio, followed by $SIBN and $AXGN. During the quarter the fund opened 2 new positions and exited 6 — including a new stake in $TRVI and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (80.0% of disclosed assets). All figures are sourced directly from First Light Asset Management, LLC’s Form 13F-HR filing with the SEC under CIK 1600004.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 34.3#2,353
Quality
$179.2M12,279,523 sh - 42.7#2,005
Quality
$132.6M8,127,985 sh - 40.8#2,089
Quality
$126.9M2,748,361 sh - —
Quality
$123.5M930,289 sh - —
Quality
$118.0M771,901 sh - 33.9
Quality
$74.9M727,933 sh - —
Quality
$69.1M1,360,750 sh - 39.0
Quality
$66.3M441,586 sh - 27.0
Quality
$54.7M6,282,804 sh - 8.7
Quality
$54.3M3,023,256 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 NEOGENOMICS INC$NEO | 34.3#2,353 | $179.2M | 12,279,523 |
 SI-BONE, Inc.$SIBN | 42.7#2,005 | $132.6M | 8,127,985 |
 Axogen, Inc.$AXGN | 40.8#2,089 | $126.9M | 2,748,361 |
 Apogee Therapeutics, Inc.$APGE | — | $123.5M | 930,289 |
 PALVELLA THERAPEUTICS, INC.$PVLA | — | $118.0M | 771,901 |
 Twist Bioscience Corp$TWST | 33.9 | $74.9M | 727,933 |
 Enliven Therapeutics, Inc.$ELVN | — | $69.1M | 1,360,750 |
 Guardant Health, Inc.$GH | 39.0 | $66.3M | 441,586 |
 908 Devices Inc.$MASS | 27.0 | $54.7M | 6,282,804 |
 Amylyx Pharmaceuticals, Inc.$AMLX | 8.7 | $54.3M | 3,023,256 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of First Light Asset Management, LLC's 31 positions.
Showing top 10 of 31 holdings.
Sector Allocation
Healthcare
$1.3B
Technology
$329.2M
Full Holdings — First Light Asset Management, LLC (Q2 2026)
All 31 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $NEO | NEOGENOMICS INC | $179.2M | 10.9% | +26% | 34.3 |
| 2 | $SIBN | SI-BONE, Inc. | $132.6M | 8.1% | +52% | 42.7 |
| 3 | $AXGN | Axogen, Inc. | $126.9M | 7.7% | -31% | 40.8 |
| 4 | $APGE | Apogee Therapeutics, Inc. | $123.5M | 7.5% | +61% | — |
| 5 | $PVLA | PALVELLA THERAPEUTICS, INC. | $118.0M | 7.2% | -21% | — |
| 6 | $TWST | Twist Bioscience Corp | $74.9M | 4.5% | -17% | 33.9 |
| 7 | $ELVN | Enliven Therapeutics, Inc. | $69.1M | 4.2% | +574% | — |
| 8 | $GH | Guardant Health, Inc. | $66.3M | 4.0% | +58% | 39 |
| 9 | $MASS | 908 Devices Inc. | $54.7M | 3.3% | +3% | 27 |
| 10 | $AMLX | Amylyx Pharmaceuticals, Inc. | $54.3M | 3.3% | -5% | 8.7 |
| 11 |  $WGS | GeneDx Holdings Corp. | $53.8M | 3.3% | +223% | 35.4 |
| 12 |  $SLP | Simulations Plus, Inc. | $51.1M | 3.1% | +6% | 55.2 |
| 13 |  $TNDM | TANDEM DIABETES CARE INC | $51.1M | 3.1% | +157% | 42.8 |
| 14 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $50.9M | 3.1% | +25% | 25.5 |
| 15 |  $NPCE | NeuroPace Inc | $45.5M | 2.8% | +16% | 32.4 |
| 16 |  $EWTX | Edgewise Therapeutics, Inc. | $44.5M | 2.7% | +9% | — |
| 17 |  $ANAB | ANAPTYSBIO, INC | $39.3M | 2.4% | +3% | 48.4 |
| 18 |  $TRVI | Trevi Therapeutics, Inc. | $39.1M | 2.4% | NEW | — |
| 19 |  $SEPN | Septerna, Inc. | $32.3M | 2.0% | +31% | 59.2 |
| 20 |  $TLSI | TriSalus Life Sciences, Inc. | $29.8M | 1.8% | +29% | 29.7 |
| 21 |  $TECX | Tectonic Therapeutic, Inc. | $27.5M | 1.7% | +24% | — |
| 22 |  $HCAT | Health Catalyst, Inc. | $25.5M | 1.6% | -1% | 21.9 |
| 23 |  $BFLY | Butterfly Network, Inc. | $22.2M | 1.4% | -1% | 33.8 |
| 24 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $21.2M | 1.3% | -20% | 33.9 |
| 25 |  $PCVX | Vaxcyte, Inc. | $20.1M | 1.2% | +143% | — |
| 26 |  $IRTC | iRhythm Holdings, Inc. | $19.9M | 1.2% | -1% | 54.8 |
| 27 |  $OMCL | OMNICELL, INC. | $18.8M | 1.1% | -8% | 51.9 |
| 28 |  $ATRC | AtriCure, Inc. | $15.9M | 1.0% | -22% | 59 |
| 29 |  $KRMD | KORU Medical Systems, Inc. | $14.2M | 0.9% | -10% | 40.4 |
| 30 |  $TCMD | TACTILE SYSTEMS TECHNOLOGY INC | $13.8M | 0.8% | NEW | 56.1 |
| 31 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $9.5M | 0.6% | -2% | 33.9 |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for First Light Asset Management, LLC including:
Track First Light Asset Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for First Light Asset Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: First Light Asset Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For First Light Asset Management, LLC (SEC CIK: 1600004), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in First Light Asset Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.